VCBeat Health
Contact Us
Home
China Healthcare Select
Insights
MNC China Lens
Vertical Industries
Services
Partnership Development
Market Entry Advisory
Ecosystem Engagement Advisory
About VCBeat
Why VCBeat
Log In
Home
Sino Biopharmaceutical: Subsidiary's FRα-Targeting ADC SYS6041 Granted IND Approval for Ovarian Cancer Combination Therapy
Sino Biopharmaceutical: Subsidiary's FRα-Targeting ADC SYS6041 Granted IND Approval for Ovarian Cancer Combination Therapy
Jun 15, 2026 17:20 CST Updated 17:47
Share:
